From Identifying Genetic Material to the Human Genome: Decisive Turning Points in Modern Life Sciences Missed by the Nobel Prize
Background
Every year in early October, when the Nobel Prize winners in Physiology or Medicine are announced, the eyes of the global scientific community turn toward Stockholm. While it is the highest honor awarded to researchers who have contributed to human welfare, the 120-year history of the Nobel Prize is not a complete record of advancements in life sciences. There are numerous cases where decisive studies that shook the mainstream theories of academia were permanently excluded due to the Nobel Committee's conservative evaluation criteria, contemporary scientific skepticism, and anachronistic selection regulations.
The international academic journal Science, in conjunction with the Nobel Prize announcement week of 2026, focused on representative discoveries that had reshaped the landscape of modern biomedical science yet remained unrecognized by the Nobel Committee. This analysis does not merely record past oversights. A catalyst that reveals the structural disconnect between the modern scientific ecosystem, where large-scale convergent research has become the norm, and the individual-centric award regulations established in the late 19th century.
Key Discoveries
One of the most glaring omissions is the research by Oswald Avery, Colin MacLeod, and Maclyn McCarty in 1944, which identified the nature of genetic material. At the time, the scientific community believed that proteins composed of 20 types of amino acids transmitted genetic information, while deoxyribonucleic acid (DNA), composed of 4 bases, was merely a simple scaffold. The decisive turning point that challenged this common belief was the Avery team's pneumococcus transformation experiment.
The researchers injected extracts of pathogenic S-type Streptococcus pneumoniae, inactivated by heat, into non-pathogenic R-type strains. Even after treatment with the proteases trypsin and chymotrypsin, and the ribonuclease RNase, R-type strains were still transformed into S-type. Conversely, when treated with DNase, the transformation capability was lost. This was the first evidence proving that DNA is the essence of genetic information. The Nobel Committee delayed the decision due to the skepticism of some reviewers who were obsessed with the possibility of protein contamination, and the opportunity vanished when Avery passed away in 1955.
The structural exclusion that emerged with the advent of Big Science is also a symbolic event. The Human Genome Project (HGP), which decoded 3 billion base pairs over 13 years from 1990 to 2003, was a watershed moment in modern genomics. Nevertheless, the limitation on joint awards for a single field to a maximum of three individuals acted as an obstacle. The fact that the achievements of thousands of researchers and large consortia could not be compressed into the domain of a few individuals.
Neuroscience research that elucidated the biological mechanisms underlying psychological disorders and brain diseases also escaped the Nobel spotlight. The biopsychological discovery that synaptic signal transmission and chemical interactions between neurons govern emotion and cognitive behavior laid the foundation for psychiatry. However, it has not received full attention due to the long-standing boundary between physiology and psychology.
Significance and Outlook
Avery’s discovery of transformation catalyzed the construction of the DNA double helix model by James Watson and Francis Crick, and the HGP’s base sequence map became the foundational pillar supporting genome medicine based on Next-Generation Sequencing (NGS). Regardless of official recognition by the Nobel Prize, the intellectual legacy left by these studies functions as the core engine of the modern biopharmaceutical industry. The value overlooked by the contemporary review committee has since become established as the standard for new drug development.
This analysis reveals the disconnect between the Nobel Prize's operational mechanisms and the practices of modern scientific research. Modern life science research has evolved into large-scale collaborations combining experts in bioinformatics, computer engineering, and clinical medicine, rather than the intuition of isolated geniuses. Critics point out that as long as the three-person limit for awards and the principle against posthumous awards are mechanically upheld, the contradiction of large-scale projects being overlooked will persist. This is driven by the growing demand that the prestigious award, which commemorates the frontiers of human knowledge, establish a flexible evaluation system to accommodate paradigm shifts of the era.
Major discoveries, including the role of DNA, the biological basis of psychology, and the human genome, missed out on science’s top recognition
The principles of transformation identified by Avery and the base sequence map of the HGP are core assets that permeate the entire drug development pipeline of the modern biopharmaceutical industry. In the field of precision oncology, the entire genome is analyzed from a patient's tumor biopsy data to find target mutations, and targeted anticancer drugs or antibody-drug conjugates (ADCs) are administered accordingly. The standard human genome map established by the HGP serves as a reference point, enabling the identification of gene deletions or point mutations to formulate optimal treatment strategies. Furthermore, the mechanism of transformation, which introduces external genetic material via DNA, became the direct theoretical root for the production process of gene replacement therapies using Adeno-associated virus (AAV) vectors. From treatments for rare genetic diseases to mRNA platform vaccines, these discoveries go beyond basic laboratory research to substantially underpin the biopharmaceutical industry, which is worth hundreds of billions of dollars annually.